Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026

Odyssey Therapeutics reported Phase IIa trial data for OD-001, showing better efficacy at 20 mg dose. The company plans Phase IIb and combination studies for 2027 readouts. No serious adverse events were reported. Odyssey has $433M in cash, funding operations into 2H 2028. The company also plans to file a CTA for OD-002 this year.

Odyssey Therapeutics (ODTX) reported Phase 2a data for OD-001, an oral treatment for ulcerative colitis, showing significant reduction in disease severity and positive biomarker changes. The study met its primary endpoint, with 27% clinical remission and 61% clinical response rates at the 20 mg dose. The company plans to advance to Phase 2b and Phase 2a combination studies. ODTX stock closed at $18.10, up 5.42%.

Odyssey Therapeutics (ODTX) announced that its drug candidate OD-001 met the primary endpoint in a Phase 2a study for ulcerative colitis, showing a 2.4-point reduction in modified Mayo score and 27% clinical remission rate. The drug was well tolerated. ODTX plans further trials, with data expected in 2027. The stock closed at $18.10, up 5.42%.

Odyssey Therapeutics (ODTX) reported Phase 2a trial results for OD-001 in ulcerative colitis. The 56-patient trial met its primary endpoint, with 27% clinical remission in the 20 mg group. ODTX shares were down 1.66% premarket.

Odyssey Therapeutics reported Phase 2a trial results for OD-001 in ulcerative colitis, meeting its primary endpoint. 27% of patients in the 20 mg group achieved clinical remission, with the drug generally well tolerated. The company plans Phase 2b and 2a trials, with results expected in late 2027, according to the press release.

Odyssey Therapeutics reported positive Phase 2a results for OD-001, meeting its primary endpoint with a 2.4-point mean modified Mayo score reduction. The 20 mg BID dose showed 27% clinical remission and 61% clinical response. Biomarkers indicated reduced inflammation, and the treatment was well-tolerated. The company plans to advance to Phase 2b with this dose.